He Hemolytic Uremic Syndrome (HUS) It is a serious disease characterized by thrombotic microangiopathy. This means that small blood clots form in the smallest blood vessels in the body.
These clots can cause:
Most common cause: Most cases in children (more than 90%) are caused by infection with a strain of the bacteria Escherichia coli which produces Shiga toxin (STEC), often after an episode of bloody diarrhea. This is known as typical SHU or D+.
HUS should be suspected in any child who presents the classic triad, especially after an episode of diarrhea (usually bloody).
Microangiopathic Hemolytic Anemia
(Paleness, jaundice, schistocytes)
Thrombocytopenia
(Petechiae, ecchymosis)
Acute Kidney Injury
(Oliguria, anuria, edema, HBP)
| Study | Expected Finding in SHU |
|---|---|
| Complete Blood Biometry | Anemia (Hb < 10 g/dL), Thrombocytopenia (< 150,000/µL) |
| Peripheral Blood Smear | Presence of schistocytes ("bitten" cells) |
| Blood Chemistry | Elevation of Creatinine and BUN |
| Hemolysis Tests | Elevated LDH, Decreased Haptoglobin, Elevated indirect bilirubin |
| Serum electrolytes | Hyperkalemia, hyponatremia, metabolic acidosis |
| General Urine Examination | Hematuria, proteinuria |
| Coproparasitoscopic and Shiga toxin in feces | STEC-HUS confirmation |
Key Principle
The mainstay of treatment is support management. There is no specific curative therapy for typical HUS (Shiga toxin-associated).
It is crucial to maintain euvolemia. Avoid water overload.
| 1st Line Medication | Presentation | Dose |
|---|---|---|
| Amlodipine | Tablets 5 mg | 0.1 - 0.2 mg/kg/day, divided into 1-2 doses. Max 0.6 mg/kg/day. |
| Labetalol IV (HBP Crisis) | Sol. Injectable 5 mg/ml | Bolus: 0.2-1 mg/kg/dose. Infusion: 0.25-3 mg/kg/hour. |
Re-evaluation must be continuous.
The reference must be IMMEDIATE before any of the following data:
The nephrologist will evaluate the need for renal replacement therapies and specific treatments.
| Therapeutic Option | Main Indications |
|---|---|
| Peritoneal Dialysis / Hemodialysis | Refractory anuria, fluid overload, symptomatic uremia, hyperkalemia or acidosis. |
aHUS requires a different approach, focusing on complement inhibition.
| Medicine | Presentation | Dosage (example) |
|---|---|---|
| Eculizumab | Sol. Injectable 300 mg/30 ml | Dose by weight. Ex: 5-10 kg: 300 mg initial, then maintenance. |
*Eculizumab is a highly specialized drug and its use is exclusive to pediatric nephrologist/hematologist.
1. What is the classic HUS triad?
2. What is the mainstay of treatment in typical HUS?
3. What finding is characteristic in the peripheral blood smear in HUS?
4. What drugs are contraindicated in the diarrheal phase due to the risk of precipitating HUS?
5. What is an IMMEDIATE indication for referral to pediatric nephrology?